XOMA (XOMA) Price Target Lowered to $16.26 at S&P Equity Research

XOMA (NASDAQ:XOMA) had its price objective trimmed by S&P Equity Research from $18.74 to $16.26 in a research note issued to investors on Tuesday morning.

Several other brokerages also recently weighed in on XOMA. Zacks Investment Research raised XOMA from a sell rating to a buy rating and set a $27.00 target price for the company in a research note on Wednesday, May 16th. HC Wainwright set a $49.00 target price on XOMA and gave the stock a buy rating in a research note on Thursday, May 10th. Wedbush reaffirmed an outperform rating and set a $33.00 target price on shares of XOMA in a research note on Wednesday, August 8th. Cowen reaffirmed a hold rating on shares of XOMA in a research note on Thursday, May 10th. Finally, TheStreet raised XOMA from a d rating to a c- rating in a research note on Tuesday, June 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $31.32.

Shares of XOMA stock opened at $17.41 on Tuesday. The company has a debt-to-equity ratio of 3.06, a current ratio of 12.46 and a quick ratio of 12.46. The company has a market cap of $154.57 million, a PE ratio of 17.69 and a beta of 2.64. XOMA has a 1-year low of $7.38 and a 1-year high of $37.25.

XOMA (NASDAQ:XOMA) last announced its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to analyst estimates of $4.57 million. XOMA had a return on equity of 379.39% and a net margin of 43.55%. sell-side analysts forecast that XOMA will post -0.94 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd raised its stake in XOMA by 57.6% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after purchasing an additional 7,349 shares during the last quarter. ClariVest Asset Management LLC raised its stake in XOMA by 25.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 23,500 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 4,700 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in XOMA in the 2nd quarter valued at $568,000. BlackRock Inc. raised its stake in XOMA by 151.6% in the 2nd quarter. BlackRock Inc. now owns 448,856 shares of the biotechnology company’s stock valued at $9,373,000 after purchasing an additional 270,437 shares during the last quarter. Finally, GSA Capital Partners LLP raised its stake in XOMA by 135.7% in the 2nd quarter. GSA Capital Partners LLP now owns 28,315 shares of the biotechnology company’s stock valued at $591,000 after purchasing an additional 16,300 shares during the last quarter. 41.65% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

See Also: NASDAQ

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply